A new study published in The Lancet has found that raising HDL levels may not make a difference to heart...
NICE has published revised draft guidance on Ezetrol (ezetimibe), from Merck Inc, that in essence reverts to the guidance being...
Egalet Corporation has announced that the FDA has approved Arymo ER (morphine sulfate) extended-release (ER) tablets C-II for the management...
Egalet Corporation announced that the FDA has accepted the new drug application (NDA) for Arymo ER (morphine sulfate) extended-release tablets....
Pain Therapeutics announced two new publications for its drug candidate, Remoxy ER (extended-release oxycodone). The studies are published in Journal...
The FDA has, on 25 October 2013, approved Zohydro ER (hydrocodone bitartrate extended-release capsules) from Zogenix, for the management of...
Osmotica Pharmaceutical announced that the FDA has approved Osmolex ER (amantadine HCl extended release), for the treatment of Parkinson's disease...
Teva Pharmaceutical has announced the FDA approved Vantrela ER (hydrocodone bitartrate) extended-release tablets [CII] formulated with Teva’s proprietary abuse deterrence...
Trevi Therapeutics announced statistically significant results from its oral Nalbuphine ER Phase II/III trial for the treatment of moderate to...
Endo International plc continues to believe in the safety, efficacy, and favorable benefit-risk profile of Opana ER (oxymorphone hydrochloride extended...